REVIEW ARTICLE

Legumes and pulses - a scoping review for Nordic Nutrition Recommendations 2023

Liv Elin Torheim1* and Lars T. Fadnes2

1Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway; 2Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Popular scientific summary

Abstract

Consumption of legumes and pulses is associated with various health outcomes. Therefore, when updating the Nordic Nutrition Recommendations (NNR), summarizing the best available evidence on key health outcomes regarded as relevant for the Nordic and Baltics related to the consumption of legumes was essential. The aim of this scoping review was to evaluate the updated evidence on the effect of the consumption of legumes and pulses on various health outcomes, as well as their dose-response relationship in updated systematic reviews and meta-analyses. The scoping review is built on a de novo systematic review published in 2023 and additional searches on the consumption of legumes and pulses and its various health outcomes, including cardiovascular disease (CVD), cancer, type 2 diabetes, and obesity. Current available evidence shows that the consumption of legumes and pulses is associated with a lower risk of several cancers (evidence: low-moderate), and lower all-cause mortality (evidence: moderate). The associations with CVDs are neutral or inverse, with studies generally showing favourable changes in biomarkers for CVDs. Legume consumption is associated with a lower risk of obesity (evidence: low). For type 2 diabetes, no association was found with incidence, but trials on consumption of legumes and pulses and biomarkers generally indicated protective effects. Overall, the current evidence supports dietary recommendations to increase the consumption of legumes and pulses.

Keywords: pulses; legumes; Fabaceae; dietary recommendations

 

Citation: Food & Nutrition Research 2024, 68: 10484 - http://dx.doi.org/10.29219/fnr.v68.10484

Copyright: © 2024 Liv Elin Torheim and Lars T. Fadnes. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

Received: 20 October 2022; Revised: 17 May 2023; Accepted: 3 January 2024; Published: 26 March 2024

Competing interests and funding: The authors have not received any funding or benefits from industry to conduct this study, and report no conflicts of interests. The authors received a small reimbursement from the Norwegian Directorate of Health for work linked to this article.

*Liv Elin Torheim, Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway. Email: livelin.torheim@fhi.no

To access the supplementary material, please visit the article landing page

 

Legumes is a collective term for plants under the Fabaceae botanical family, and include various types of beans, lentils, peas, and soybeans (1). Pulses refer to the dry, edible seeds from legume plants, and include species such as beans, lentils, and peas (2). Fresh beans and peas as well as soy products are classified under legumes, but not necessarily under pulses. Peanuts classify botanically as legumes, but are usually classified as nuts in nutritional research in line with their culinary definition (3). In this scoping review, we use the term legumes referring to lentils, peas, and beans including soybeans. Legumes are good sources of proteins, complex carbohydrates, and fibre, and are generally low in fat and saturated fatty acids. Legumes contain between 17 and 40% protein (dry matter). Soybean has a high protein content (37%), and the protein has high digestibility and a complete protein quality containing all indispensable amino acids (4, 5). Legumes are rich in lysine; however, most are limited in one or more indispensable amino acids, typically the sulphur-containing amino acids, methionine and cysteine. Grains have a complementary amino acid profile to legumes, being rich in methionine and cysteine but low in lysine. Thus, consuming a varied diet with both legumes and cereals will for most ensure an adequate protein intake. The content of micronutrients differs between varieties, but several legumes are rich in folate, thiamine, potassium, magnesium, iron, and zinc, as well as bioactive compounds such as phytochemicals (1, 6). Legumes, and especially pulses, may contain anti-nutritional factors that can interfere with the absorption of nutrients and reduce the bioavailability of certain minerals. Anti-nutritional factors, such as phytates, trypsin inhibitors and tannins, can be reduced through soaking, cooking and fermentation (4).

Legumes form an important part of the food culture in many countries, but in many settings, including the Nordic and Baltic countries, the consumption is relatively low (7). Legumes are increasingly used as an alternative to meat, being a nutritious food with high protein content and a low environmental footprint (8). Protein concentrates and isolates from legumes are increasingly being used in meat analogues (9). These products may contain less fibres and have a high level of salt, and thus not necessarily have the same healthy nutritional profile as legumes that have been lightly processed through, for example, cooking. The protein digestibility of plant-based products can also change with processing (9). There has been an expansion in research on the health effects of legumes over the past years. The Nordic Nutrition Recommendations (NNR) from 2012 did not give recommendations for legumes, but legumes were mentioned several times. The Nordic countries have, to a varying degree, included legumes in their national dietary guidelines. The Norwegian dietary guidelines based on NNR2012 do not include legumes (10), whereas Sweden and Finland encourage the consumption of legumes, and Denmark, Estonia, Iceland, and Latvia give specific recommendations in amounts (7).

The objective of this scoping review is to transparently report the updated evidence on the consumption of legumes and associated health outcomes regarded as relevant for the Nordic and Baltic countries, as well as dose-response relationship between legumes and various health outcomes presented in updated systematic reviews and meta-analyses (Box 1).

Box 1. Background papers for Nordic Nutrition Recommendations 2023

Methods

Literature searches were screened to extract relevant evidence. No relevant, independent systematic reviews by multidisciplinary experts commissioned by national food or health authorities or international food and health organisations were identified by the NNR2023 Committee (11). However, a de novo systematic review for NNR2023 was conducted (3). The de novo systematic review screened 10,771 articles from MEDLINE, Embase, Cochrane, and Scopus. In addition, nine records were identified through screening articles in other systematic reviews on the topic. The review included 47 papers of which 42 were included in the meta-analyses on 25 unique cohorts with a total of 2,081,423 participants, and 14 randomized controlled trials with a total of 715 participants. Health outcomes presented were cardiovascular disease (CVD) and type 2 diabetes, and their associated biomarkers. Associations for high versus low consumption, per serving, and dose-response relationships were presented.

In addition to the de novo systematic review, we conducted additional searches for systematic reviews and meta-analyses on the health outcomes cancer, obesity, dementia, and all-cause mortality. We used a culinary definition of legumes including peas, lentils, and beans (but excluding coffee and cacao beans). Peanuts are not covered as they are culinarily considered as a nut. MEDLINE was searched with the following search string: (pulses[MeSH Terms] OR legumes[MeSH Terms] OR “food groups”) AND (cancer OR Neoplasms[MeSH Terms] OR obesity[MeSH Terms] OR dementia[MeSH Terms]) AND (meta-analysis[filter] OR systematic review[filter]). The search identified 101 hits that were screened, and the most recent and comprehensive systematic reviews for the above-mentioned outcomes are presented below. In this search, one umbrella review and systematic review and meta-analysis of prospective cohorts commissioned by European Association for the Study of Diabetes (EASD) published in 2019 was found (12). The searches for the de novo systematic review included articles indexed until the 16th of May 2022 and, correspondingly, our additional search included meta-analyses until the 24th of September 2022. The quality of the included articles in the systematic reviews used in the systematic search was assessed with the AMSTAR 2 tool with an NNR2023 adaption (13, 14), with the qualities categorised into high/moderate/low/very low. The de novo systematic review examined strength of evidence according to the World Cancer Research Fund criteria (15). Studies covered by other meta-analyses and systematic reviews and thus not selected are listed in Supplementary Table 1.

Dietary intake in the Nordic and Baltic countries

In the Nordic and Baltic countries, the intake of legumes is generally relatively low, with mean consumption among adults ranging from 1 to 3 g/day in Denmark and Norway to 17–18 g in Latvia (16, 17). However, it is difficult to accurately assess the exact intake of legumes in dietary surveys because of daily variation in intake. Furthermore, foods from this food group could be included in various dishes and processed foods in amounts not always known to the consumer. Comparisons between countries may be further confounded due to differences in how legumes are classified.

Health outcomes relevant for Nordic and Baltic countries

CVD and cancers are the two leading causes of death in the Nordic and Baltic countries (18, 19). As summarized in both the de novo systematic review for NNR2023 and the systematic review commissioned by EASD (3, 12), consumption of legumes is associated with longevity (reduced mortality), and legumes including soy are either inversely or neutrally associated with hypertension and coronary heart disease (CHD) (very low evidence, Table 1 & Fig. 1). Higher compared to lower consumption of legume and soy products such as tofu was generally associated with a slightly lower risk for CVD (Table 1). For several cancers and cancer-related mortalities, there were inverse associations with legume consumption including soy (mostly low evidence). There was no clear conclusion on type 2 diabetes. The details of these and other health outcomes will be presented below.

Table 1. Consumption of legumes and association to various health morbidities and mortalities from cardiovascular diseases, cancer, type 2 diabetes and obesity, and other outcomes from meta-analyses
First author Year Exposure Outcome Unit Difference (95% CI) Participants Evidence AMSTAR 2-NNR
Thorisdottir 2023 Legumes CVD (incidence & mortality) HL RR 0.95 (0.86–1.06) 9 studies High
Thorísdottír 2023 Legumes CVD mortality HL RR 1.03 (0.89–1.20) 6 studies High
Thorísdottír 2023 Legumes CHD (incidence & mortality) HL RR 1.00 (0.95–1.05) 10 studies High
Thorísdottír 2023 Legumes CHD incidence HL RR 0.99 (0.94–1.05) 7 studies High
Thorísdottír 2023 Legumes Stroke (incid. & mortality) HL RR 0.98 (0.91–1.05) 9 studies High
Thorísdottír 2023 Legumes Stroke incidence HL RR 0.99 (0.91–1,09) 6 studies High
Thorísdottír 2023 Legumes T2D HL RR 0.90 (0.77–1.06) 9 studies High
Thorísdottír 2023 Legumes Total cholesterol IvsC −0.22 mmol/L (−0.32, −0.13) 14 studies High
Thorísdottír 2023 Legumes LDL-cholesterol IvsC −0.19 mmol/L (−0.27, −0.22) 12 studies High
Thorísdottír 2023 Legumes HDL-cholesterol IvsC ns 14 studies High
Thorísdottír 2023 Legumes Triglycerides IvsC ns 12 studies High
Thorísdottír 2023 Legumes Fasting glucose IvsC −0.19 mmol/L (−0.33, −0.5) 10 studies High
Thorísdottír 2023 Legumes Insulin IvsC ns 10 studies High
Thorísdottír 2023 Legumes HOMA-IR IvsC −0.30 (−0.60, 0.00) 7 studies High
Viguiliouk 2019 Legumes CVD incidence HL RR 0.92 (0.85–0.99) 7 studies, 231,353 participants, 10,261 cases Low High
Viguiliouk 2019 Legumes CVD mortality HL RR 0.97 (0.89–1.06) 12 studies, 940,756 participants, and 16,168 cases. Very low High
Viguiliouk 2019 Legumes CHD incidence HL RR 0.90 (0.83–0.99) 10 studies, 306,814 unique participants, and 7786 cases Very low High
Viguiliouk 2019 Legumes CHD mortality HL RR 0.94 (0.82–1.08) 9 studies, 224,592 participants, and 3,331 cases. Very low High
Viguiliouk 2019 Legumes Myocardial infarction incidence HL RR 0.90 (0.74–1.10) 4 studies, 202,528 participants, and 2,585 cases Very low High
Viguiliouk 2019 Legumes Stroke incidence HL RR 0.98 (0.86–1.11) 8 studies, 342,079 participants, and 8,570 cases. Very low High
Viguiliouk 2019 Legumes Stroke mortality HL RR 0.89 (0.78–1.03) 6 studies, 168,504 participants, and 2,384 cases Very low High
Viguiliouk 2019 Legumes T2D HL RR 0.93 (0.83–1.05) 9 studies, 259,325 participants, and 10,457 cases. Very low High
Viguiliouk 2019 Legumes Hypertension HL RR 0.91 (0.86–0.97) 7 studies, 288,352 participants, and 83,284 cases Very low High
Schlesinger 2019 Legumes Overweight/ obesity HL RR 0.87 (0.81–0.94) 1 study, 18,146 participants, 1,825 cases Very low High
Schlesinger 2019 Legumes Weight gain 50 g/day RR 0.88 (0.84–0.93) 1 study, 18,146 participants Very low High
Schwingshackl 2017 Legumes Mortality HL RR 0.96 (0.93–1.00) 17 studies, 53,085 cases Moderate High
Schwingshackl 2017 Legumes Mortality 50 g/day RR 0.96 (0.90–1.01) 17 studies, 53,085 cases Moderate High
Kazemi 2021 Legumes Breast cancer HL RR 0.95 (0.87–1.05) 4 studies Low High
Kazemi 2021 Soy Breast cancer 30 g/day RR 0.96 (0.94–0.99) 7 studies, 4,055 cases Moderate High
Kim 2016 Legumes Body weight 132 g/day −0.34 kg (−0.63, −0.04) 21 trials, 940 participants Low High
Wang 2021 Soy Gastric cancer HL RR 0.64 (0.51–0.80) 13 studies Moderate
Zhong 2018 Soy isoflavones Endometrial cancer HL OR 0.81 (0.74–0.89) 13 studies, 178,947 participants, 7,067 cases Low Moderate
Li 2017 Legumes Prostate cancer HL RR 0.85 (0.75–0.96) 8 studies, 281,034 participants, 10,234 cases Low Low
Li 2017 Legumes Prostate cancer 20 g/day −3.7% (95% CI: −5.8%, −1.5%) 8 studies, 281,034 participants, 10,234 cases Low Low
Nachvak 2019 Soy isoflavones Mortality HL RR 0.90 (0.82–0.98) 5 studies, 51,270 participants, 5,269 cases Moderate
Nachvak 2019 Soy Mortality HL RR 0.90 (0.77–1.04) 5 studies, 78,381 participants and 24,497 deaths Moderate
Nachvak 2019 Soy CVD mortality HL RR 0.91 (0.81–1.03) 6 studies, 178,394 participants, 11,628 deaths Moderate
Nachvak 2019 Soy Cancer mortality HL RR 0.90 (0.81–1.00) 9 studies, 165,288 participants, 9,804 deaths Moderate
Nachvak 2019 Soy isoflavones Cancer mortality HL RR 0.80 (0.67–0.94) 7 studies, 16,683 participants, 2,228 deaths Moderate
Nachvak 2019 Soy isoflavones Breast cancer mortality HL RR 0.83 (0.69–0.99) 6 studies, 16,239 participants and 1,910 deaths Moderate
Nachvak 2019 Soy Gastric cancer mortality RR 0.49 (0.35–0.68) 3 studies Moderate
Nachvak 2019 Soy Lung cancer mortality RR 0.79 (0.71–0.87) 3 studies Moderate
Nachvak 2019 Soy Colorectal cancer mortality RR 0.59 (0.41–0.84) 2 studies Moderate
Nachvak 2019 Soy Hepatic cancer mortality RR 0.89 (0.71–1.12) 2 studies Moderate
Jin 2022 Legumes Colorectal cancer risk HL RR 0.90 (0.83–0.98) 29 studies, 1,688,603 participants, 20,906 cases Low Low
Jin 2022 Legumes Colorectal cancer risk 100 g/day RR 0.79 (0.64–0.97) 29 studies, 1,688,603 participants, 20,906 cases Low Low
Wang 2013 Legumes Colorectal adenoma risk HL RR 0.83 (0.75–0.93) 14 studies, 101,856 participants, and 8,380 cases Low
The consumption comparison is listed as high versus low consumption (HL), intervention versus control group (I vs. C), or specific intake level.

Fig 1
Fig. 1. Summary of associations of relative risks ratios (RRR) from the most comprehensive meta-analyses between high compared to low (HL) consumption or dose-response (in specific grams) of legumes or soy, and morbidities and mortalities from cancer, cardiovascular disease, obesity, and type 2 diabetes (listed by first author & publication year). Number of studies, participants (n), and number of cases are also specified.

Cardiovascular disease

Meta-analyses of prospective cohort studies in the de novo systematic review on either total CVD, CHD, or stroke showed no associations comparing higher with lower legume consumption and no dose-response relationship (Table 1 & Fig. 1). The de novo systematic review did not include consumed soy products. The authors further cautioned that the result needs to be interpreted in the light of the generally low legume consumption reported in the cohorts. Randomized controlled trials on approximately >120–150 g/day of legumes indicate biological effects on biomarkers for disease, with these meta-analyses showing lowering of total cholesterol (−0.22 mmol/L (95% confidence interval [CI]: −0.32, −0.13) and LDL-cholesterol (−0.19 mmol/L, 95% CI: −0.27, −0.11), but no significant effect on triglycerides or high-density lipoprotein (HDL-C). Overall, the findings from the systematic review were mixed, with high heterogeneity and mostly moderate/some concern for risk of bias. The authors considered the evidence strong in supporting the absences of any adverse effects of legume intake in relation to CVD or type 2 diabetes. Furthermore, since legume interventions were suggested to have protective effects on blood lipids, the conclusion of the de novo systematic review was that the evidence was inconclusive on the causal relationship. The evidence for associations between legume consumption and CVD was judged as limited – no conclusion.

The EASD commissioned systematic review found that the highest compared with the lowest level of consumption of legumes including soy products, was associated with significant decreases in CVD (RR: 0.92; 95% CI: 0.85, 0.99), CHD (RR: 0.90; 95% CI: 0.83, 0.99) and hypertension (RR: 0.91; 95% CI: 0.86, 0.97) incidence (12). There was no association with myocardial infarction or stroke, or CVD, CHD, and stroke mortality. The lowest quantile of intake of dietary pulses with or without other legumes ranged from a median of 0 g/day for myocardial infarction incidence to 16.2 g/day for obesity incidence. The highest quantile of intake of dietary pulses with or without other legumes ranged from a median of 27.8 g/day for CVD mortality to 213 g/day for myocardial infarction incidence. The overall certainty of the evidence was graded as ‘low’ for CVD incidence and ‘very low’ for all other outcomes. The authors concluded that current evidence shows that legumes are associated with reduced CVD incidence with low certainty and reduced CHD and hypertension. Contrary to the de novo systematic review, the EASD systematic review included both peanuts and soybean products (e.g. tofu), which might explain the discrepancy in the findings (Tables 12 & Fig. 1).

Table 2. Summary of relevant findings regarding legumes and health from non-meta-analysis systematic reviews/umbrella reviews
First author Year Exposure Outcome Summary of results
Li N 2020 Soy isoflavones All health outcomes Umbrella review including 114 meta-analyses and systematic reviews. Generally, soy and isoflavone consumption is more beneficial than harmful. Beneficial associations were identified for cancers, cardiovascular disease, gynaecological, metabolic, musculoskeletal, endocrine, neurological, and renal outcomes.
Martini 2021 Legumes All health outcomes Umbrella review including six meta-analyses of observational studies. Concludes with possible association with decreased risk of colorectal cancer and CHD,
Messina 2022 Isoflavones and soy Hormonal effects After extensive review, the evidence does not support classifying isoflavones as endocrine disruptors.
Rafie 2017 Legumes Telomere length Two studies showed positive (beneficial) associations to telomere length and legume consumption while six showed neutral associations
Solfrizzi 2017 Legumes Cognitive performance Consumption of legumes associated with better cognitive performance (and cortical thickness)

Cancers

A high consumption of legumes including soy is inversely associated with cancer mortality and risk of several cancers (20,21,22,23,24,25,26,27) (evidence mostly weak). A high compared to low consumption of legumes is associated with a relative risk (RR) of 0.90 (95% CI: 0.83–0.98). Correspondingly, for an increase in consumption of legumes of 100 g/day, RR is 0.79 (0.64–0.97). A high consumption of soy products is associated with a slightly lower risk of breast cancer. A high consumption of soy is also inversely associated with gastric, lung, and endometrial cancers (RR 0.64 [0.51–0.80], RR 0.79 [0.71–0.87], and OR 0.81 [0.74–0.89], respectively). High consumption of legumes is inversely associated with prostate cancer (RR 0.85 [0.75–0.96]).

Type 2 diabetes

Type 2 diabetes and metabolic risk factors strongly contribute to life years lost in the Nordic and Baltic countries (18, 19). For type 2 diabetes, no association was found when comparing high and low intake of legumes in observational cohort studies in neither the de novo systematic review nor the EASF systematic review (3, 12).

Meta-analyses of randomized controlled trials with interventions increasing the intake of legumes found a significant decreased fasting glucose (−0.19 mmol/L, 95% CI: −0.33, −0.05) and insulin resistance (homeostatic model assessment for insulin resistance, −0.30, 95% CI: −0.60,−0.00) (15). The de novo SR concluded that the overall evidence for associations between consumption of legumes and risk of type 2 diabetes was considered as limited – no conclusion.

Mortality and other morbidity

A high consumption of legumes is associated with decreased mortality (RR 0.96, 0.93–1.00, evidence rated as moderate) (28). For an increase in legume consumption of 50 g/day, the corresponding RR of mortality was 0.96 (0.90–1.01). A high consumption of soy isoflavones/soy products might also be associated with a reduction in mortality (RR 0.90 (0.82–0.98) / RR 0.90 [0.77–1.04]) (27).

Related to other morbidities, a high consumption of legumes is associated with less overweight and obesity (29) (RR 0.87 [0.81–0.94], evidence very low). Further, a high consumption of legumes has been shown to be associated with better cognitive performance (30).

Mechanisms

Legumes generally contain high proportion of proteins and fibres, and some fatty acids with a composition associated with a reduction in CVD (31). They also contain several active compounds including flavonols and isoflavonols that are assumed to have anti-proliferative properties, which can explain some of the associations with cancers (27). Further, the World Cancer Research Fund has assessed the evidence that fibres are protective for colorectal cancers as strong (32). Generally, soy and isoflavone consumption is considered as more beneficial than harmful (5, 33). Further, some studies have also suggested a positive (beneficial) association between legume consumption and telomere length (34). Studies on pre-cancerous development such as colon adenomas also show similar associations as colorectal cancers (21).

A meta-analysis of trials of diets rich in legumes and the association with weight (35) mirrored the meta-analysis on overweight and obesity (29), showing significant weight reduction of −0.34 kg (95% CI: −0.63, −0.04 kg) with a consumption of 134 grams per day over 6 weeks compared to no intake.

There are also favourable associations between legume consumption and biomarkers of CVD and type 2 diabetes, including low density lipoproteins, total cholesterol, fasting glucose, and insulin sensitivity (3, 12). A systematic review assessing various biomarkers important for CVD and type 2 diabetes and ranking 10 food groups from most to least beneficial for these biomarkers, ranked legumes as second in terms of most beneficial biomarker profile behind nuts and before grains, fruits and vegetables, eggs, dairy, and fish, with red meat, and sugar-sweetened beverages on the least beneficial part of the spectrum (36). Prospective cohort studies have observed inverse associations between consumption of legumes and hypertension (12).

Food-based dietary guidelines

A high consumption of legumes, and soy in particular, is associated with a decreased risk of mortality from gastric, colorectal, breast, endometrial, and lung cancers (20,21,22,23,24,25,26,27). Inclusion of legume and soy products such as tofu, is associated with favourable biomarkers of CVD and type 2 diabetes (3, 12). They seem to be associated with a reduction in all-cause mortality and potentially CHD (3, 12, 27), although the evidence is very low, and when excluding soy products, the association between legumes and CVD is neutral (15). However, considering both the favourable changes in biomarkers together with the associations to CVD and type 2 when including soy products (3, 12), there seems to be some beneficial effects of legumes related to cardiovascular health. Legume consumption is also associated with less obesity (29); the inclusion of legumes in the diet may be beneficial for people aiming for weight loss even when diets are not intended to be calorically restricted (35). One concern has been related to hormonal effects of soy products. However, an extensive review of potential endocrine disruption, does not support such concerns (37). A risk assessment of intake of phytoestrogens found in soy products such as genistein concluded that there was no risk for exceeding a health-based guidance upper intake value in pregnant women, but that children replacing animal products with primarily soy products including soy drinks could exceed the guidance value for genistein (5). Legumes might contribute beneficially also to cognitive outcomes (30).

Allergies and related adverse reactions to most legumes are relatively uncommon (38). Reactions to soy are not uncommon, but these reactions are rarely severe. With proper food labelling and storage of food, such allergies and related reactions could be limited (38). Also, lectins found in many varieties of pulses could cause unfavourable health effects, such as nausea, vomiting, bowel pain, and diarrhoea, if beans and peas are improperly cooked or are consumed uncooked. Dried beans and peas should be soaked in water overnight before rinsed, and boiled until soft (39).

Integration

The current evidence supports legume consumption as part of healthy diets to reduce the risk of later chronic disease. Based on consumption and morbidity data in the Nordic and Baltic countries and the data on mortality, increasing the consumption of legumes might contribute to some increase in life expectancy. Sustained change in the consumption of legumes from none to 100 grams per day is associated with decreased mortality (28), with an increase in life expectancy of approximately 1 year for male and female adults in the age range 30 to 50 years (40). Legumes are further among the most sustainable diet components (13).

The current evidence has some shortcomings. Several studies have assessed sub-group analyses for soy, but few have presented specific estimates for morbidities related to consumption of other specific groups of legumes. Legume consumption in populations participating in cohort studies is in general low, making it difficult to assess health effects of high intakes. Also, for children, little evidence is available.

Overall, the current evidence supports a dietary recommendation to increase legume consumption.

References

1. Martín-Cabrejas MA. Legumes: an overview. In: Martín-Cabrejas MA, ed. Legumes: nutritional quality, processing and potential health benefits. London: Royal Society of Chemistry; 2019.
2. Food and Agriculture Organization of the United Nations. Nutritional benefits of pulses. Rome: FAO; 2016.
3. Thórisdottír B, Arnesen EK, Bärebring L, Dierkes J, Lamberg-Allardt C, Ramel A, et al. Legume consumption in adults and risk of cardiovascular disease or type 2 diabetes: a systematic review and meta-analysis. Food Nutr Res 2023; 67: 9541. doi: 10.29219/fnr.v67.9541
4. Semba RD, Ramsing R, Rahman N, Kraemer K, Bloem MW. Legumes as a sustainable source of protein in human diets. Glob Food Sec 2021; 28: 100520. doi: 10.1016/j.gfs.2021.100520
5. Bredsdorff L, Fagt S, Boberg J, Pilegaard K, Widenfalk A, Steffensen IL. Soy intake and possible adverse health effects in children and pregnant women (unborn children). Copenhagen: Nordic Council of Ministers; 2020.
6. Messina V. Nutritional and health benefits of dried beans. Am J Clin Nutr 2014; 100: s437–42. doi: 10.3945/ajcn.113.071472
7. Hughes J, Pearson E, Grafenauer S. Legumes – a comprehensive exploration of global food-based dietary guidelines and consumption. Nutrients 2022; 14(15): 3380. doi: 10.3390/nu14153080
8. Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, et al. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet 2019; 393(10170): 447–92. doi: 10.1016/S0140-6736(18)31788-4
9. Lappi J, Silventoinen-Veijalainen P, Vanhatalo S, Rosa-Sibakov N, Sozer N. The nutritional quality of animal-alternative processed foods based on plant or microbial proteins and the role of the food matrix. Trends Food Sci Technol 2022; 129: 144–54. doi: 10.1016/j.tifs.2022.09.020
10. Norwegian Directorate of Health. Anbefalinger om kosthold, ernæring og fysisk aktivitet [Recommendations for diet, nutrition and physical activity]. Oslo: Norwegian Directorate of Health; 2014.
11. Hoyer A, Christensen JJ, Arnesen EK, Andersen R, Eneroth H, Erkkola M, et al. The Nordic Nutrition Recommendations 2022 – prioritisation of topics for de novo systematic reviews. Food Nutr Res 2021; 65: 7828. doi: 10.29219/fnr.v65.7828
12. Viguiliouk E, Glenn AJ, Nishi SK, Chiavaroli L, Seider M, Khan T, et al. Associations between dietary pulses alone or with other legumes and cardiometabolic disease outcomes: an umbrella review and updated systematic review and meta-analysis of prospective cohort studies. Adv Nutr 2019; 10(Suppl_4): S308–19. doi: 10.1093/advances/nmz113
13. Blomhoff R, Andersen R, Arnesen EK, Christensen JJ, Eneroth H, Erkkola M, et al. Nordic Nutrition Recommendations 2023. Copenhagen: Nordic Council of Ministers; 2023.
14. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017; 358: j4008. doi: 10.1136/bmj.j4008
15. Thorisdottir B, Arnesen EK, Bärebring L, Dierkes J, Lamberg- Allardt C, Nwaru BI, et al. Legume consumption in adults and risk of cardiovascular disease and type 2 diabetes: a systematic review and meta-analysis. Food Nutr Res 2023, 67:9541 - doi: 10.29219/fnr.v67.9541
16. Holm Totland T, Kjerpeseth Melnæs B, Lundberg-Hallén N, Helland-Kigen KM, Lund-Blix NA, Borch Myhre J, et al. Norkost 3 En landsomfattende kostholdsundersøkelse blant menn og kvinner i Norge i alderen 18–70 år, 2010–11. Oslo: Helsedirektoratet; 2012.
17. Lemming EW, Pitsi T. The Nordic Nutrition Recommendations 2022 – food consumption and nutrient intake in the adult population of the Nordic and Baltic countries. Food Nutr Res 2022; 66: 8572. doi: 10.29219/fnr.v66.8572
18. Institute for Health Metrics and Evaluation (IHME). University of Washington. Global burden of disease (GBD) compare from Institute for Health Metrics and Evaluation (IHME). Seattle, WA. Available from: http://vizhub.healthdata.org/gbd-compare [cited 15 October 2023].
19. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392(10159): 2052–90. doi: 10.1016/S0140-6736(18)31694-5
20. Jin S, Je Y. Nuts and legumes consumption and risk of colorectal cancer: a systematic review and meta-analysis. Eur J Epidemiol 2022; 37(6): 569–85. doi: 10.1007/s10654-022-00881-6
21. Wang Y, Wang Z, Fu L, Chen Y, Fang J. Legume consumption and colorectal adenoma risk: a meta-analysis of observational studies. PLoS One 2013; 8(6): e67335. doi: 10.1371/journal.pone.0067335
22. Kazemi A, Barati-Boldaji R, Soltani S, Mohammadipoor N, Esmaeilinezhad Z, Clark CCT, et al. Intake of various food groups and risk of breast cancer: a systematic review and dose-response meta-analysis of prospective studies. Adv Nutr 2021; 12(3): 809–49. doi: 10.1093/advances/nmaa147
23. Wang Y, Guo J, Yu F, Tian Y, Wu Y, Cui L, et al. The association between soy-based food and soy isoflavone intake and the risk of gastric cancer: a systematic review and meta-analysis. J Sci Food Agric 2021; 101(13): 5314–24. doi: 10.1002/jsfa.11334
24. Zhong XS, Ge J, Chen SW, Xiong YQ, Ma SJ, Chen Q. Association between dietary isoflavones in soy and legumes and endometrial cancer: a systematic review and meta-analysis. J Acad Nutr Diet 2018; 118(4): 637–51. doi: 10.1016/j.jand.2016.09.036
25. Li J, Mao QQ. Legume intake and risk of prostate cancer: a meta-analysis of prospective cohort studies. Oncotarget 2017; 8(27): 44776–84. doi: 10.18632/oncotarget.16794
26. Martini D, Godos J, Marventano S, Tieri M, Ghelfi F, Titta L, et al. Nut and legume consumption and human health: an umbrella review of observational studies. Int J Food Sci Nutr 2021; 72(7): 871–8. doi: 10.1080/09637486.2021.1880554
27. Nachvak SM, Moradi S, Anjom-Shoae J, Rahmani J, Nasiri M, Maleki V, et al. Soy, soy isoflavones, and protein intake in relation to mortality from all causes, cancers, and cardiovascular diseases: a systematic review and dose-response meta-analysis of prospective cohort studies. J Acad Nutr Diet 2019; 119(9): 1483–500.e17. doi: 10.1016/j.jand.2019.04.011
28. Schwingshackl L, Schwedhelm C, Hoffmann G, Lampousi AM, Knuppel S, Iqbal K, et al. Food groups and risk of all-cause mortality: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2017; 105(6): 1462–73. doi: 10.3945/ajcn.117.153148
29. Schlesinger S, Neuenschwander M, Schwedhelm C, Hoffmann G, Bechthold A, Boeing H, et al. Food groups and risk of overweight, obesity, and weight gain: a systematic review and dose-response meta-analysis of prospective studies. Adv Nutr 2019; 10(2): 205–18. doi: 10.1093/advances/nmy092
30. Solfrizzi V, Custodero C, Lozupone M, Imbimbo BP, Valiani V, Agosti P, et al. Relationships of dietary patterns, foods, and micro- and macronutrients with alzheimer’s disease and late-life cognitive disorders: a systematic review. J Alzheimers Dis 2017; 59(3): 815–49. doi: 10.3233/jad-170248
31. Khrisanapant P, Kebede B, Leong SY, Oey I. A comprehensive characterisation of volatile and fatty acid profiles of legume seeds. Food 2019; 8(12): 651. doi: 10.3390/foods8120651
32. World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR). Wholegrains, vegetables and fruits. Continuous update project expert report 2018. World Cancer Research Fund; 2018.
33. Li N, Wu X, Zhuang W, Xia L, Chen Y, Zhao R, et al. Soy and isoflavone consumption and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomized trials in humans. Mol Nutr Food Res 2020; 64(4): e1900751. doi: 10.1002/mnfr.201900751
34. Rafie N, Golpour Hamedani S, Barak F, Safavi SM, Miraghajani M. Dietary patterns, food groups and telomere length: a systematic review of current studies. Eur J Clin Nutr 2017; 71(2): 151–8. doi: 10.1038/ejcn.2016.149
35. Kim SJ, de Souza RJ, Choo VL, Ha V, Cozma AI, Chiavaroli L, et al. Effects of dietary pulse consumption on body weight: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2016; 103(5): 1213–23. doi: 10.3945/ajcn.115.124677
36. Schwingshackl L, Hoffmann G, Iqbal K, Schwedhelm C, Boeing H. Food groups and intermediate disease markers: a systematic review and network meta-analysis of randomized trials. Am J Clin Nutr 2018; 108(3): 576–86. doi: 10.1093/ajcn/nqy151
37. Messina M, Mejia SB, Cassidy A, Duncan A, Kurzer M, Nagato C, et al. Neither soyfoods nor isoflavones warrant classification as endocrine disruptors: a technical review of the observational and clinical data. Crit Rev Food Sci Nutr 2022; 62(21): 5824–85. doi: 10.1080/10408398.2021.1895054
38. Versluis A, Knulst AC, Kruizinga AG, Michelsen A, Houben GF, Baumert JL, et al. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review. Clin Exp Allergy 2015; 45(2): 347–67. doi: 10.1111/cea.12328
39. Strömberg A, Öhrvik V. Lektiner i baljväxter [Lectins in legumes]. Swedish National Food Agency; 2017.
40. Fadnes LT, Økland J-M, Haaland ØA, Johansson KA. Estimating impact of food choices on life expectancy: a modeling study. PLoS Med 2022; 19(1): e1003889. doi: 10.1371/journal.pmed.1003889